Pfizer Beats Q2 Earnings Estimates, Boosts Revenue Guidance

PFE reported second-quarter 2026 revenue of $15.03 billion, above the $14.45 billion Wall Street expected, with adjusted diluted EPS of $0.77 versus a $0.68 consensus . The company also raised the midpoint of its full-year 2026 revenue guidance to a range of $60.5 billion to $62.5 billion, up from $59.5 billion to $62.5 billion previously.

The upgrade was driven largely by Pfizer's non-COVID portfolio, which management said is tracking roughly $1.5 billion ahead of prior expectations on operational strength. That offset a further pullback in COVID-related product sales, with Pfizer trimming its full-year COVID forecast to about $4 billion from roughly $5 billion as vaccine and treatment demand continues to fade .

Alongside the results, Pfizer outlined an expanded cost program, projecting an additional $2.5 billion in net savings expected from 2027 through 2029, split between $1 billion from its existing cost-realignment initiative and $1.5 billion from a new phase of manufacturing optimization. These are forward-looking targets, not savings already booked. Management reaffirmed adjusted EPS guidance of $2.80 to $3.00 for the year, which includes roughly a $0.10 impact tied to the Innovent Biologics transaction.

The quarter suggests Pfizer's legacy and newer non-COVID drugs are increasingly carrying the growth story as the pandemic-era revenue base keeps shrinking. Whether the multi-year savings plan translates into durable margin expansion, rather than simply funding reinvestment, could shape how the market values the stock heading into 2027.

Related Stocks

• PFE